Topic

Jill Wechsler is Pharm Exec's Washington Corespondent

Articles

New methods and policies necessitated by the global pandemic are slated to become permanent fixtures in FDA enforcement and regulatory programs.

Pandemic Alters FDA Inspections, Quality Oversight

Open Orphan CEO Cathal Friel talks to Pharm Exec about how the company is distinctive from traditional CROs and its role in the UK’s COVID-19 human challenge study.

Q&A: Cathal Friel, Open Orphan

's Online and European Editor. He can be reached at jupton@mjhlifesciences.com

Lorna Meldrum, Vice President, Commercial Operations, International Markets & Pandemic at Seqirus, talks about the challenges of the influenza vaccine market and how COVID-19 has highlighted that preventing ’flu is crucial for public health.

Protecting Public Health: Lorna Meldrum, Seqirus

Dr. Shankar Musunuri talks about his 25 years’ experience in biotech about his company Ocugen’s latest mission to develop, manufacture, and commercialize Bharat Biotech’s COVID-19 vaccine, COVAXIN, in the North American market.





Setting Sights on the COVID Vaccine Market: Shankar Musunuri, CEO, Ocugen

If the debate over vaccines for adults and the need for extra booster shots has been heated, FDA will face even more scrutiny over the safety and value of vaccinating children under age 12. 

The Next Big COVID Challenge: Vaccines for Children under 12

FDA’s Vaccines and Related Biological Products Advisory Committee announces its recommendations for the authorization of a third dose of the Pfizer/BioNTech Comirnaty vaccine.

Vaccine Booster Battle Reveals Rifts Among Regulators, Sponsors

White House officials recently announced a nearly $3 billion program to ramp up production of vaccines and their components to better serve patients in the U.S. and globally.

Biden Bolsters Vaccine Production in Pandemic Preparedness Plan

FDA has granted full approval for the Pfizer/BioNTech anti-COVID 19 vaccine, raising hopes that this action will help overcome the vaccine hesitancy that has plagued efforts to broadly immunize the U.S. population.

Pfizer Vaccine Approval Key to Boosting Vaccination Rates

Changes necessitated by COVID will drive unprecedented transformation of industry.

Why the Pandemic is Rewriting the Biopharma Rule Book

Still plenty to learn about the virus even after year-plus long pandemic